BFM
AVTX icon

Boothbay Fund Management’s Avalo Therapeutics AVTX Stock Holding History

Boothbay Fund Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.84M Buy
324,258
+122,131
+60% +$1.91M 0.06% 334
2025
Q4 		$3.67M Sell
202,127
-26,170
-11% -$442K 0.05% 388
2025
Q3 		$2.9M Buy
228,297
+216,976
+1,917% +$1.87M 0.04% 469
2025
Q2 		$56.5K Buy
+11,321
New +$52.9K ﹤0.01% 1346
2025
Q1 		– Sell
-163,992
Closed -$1.22M – 1404
2024
Q4 		$1.22M Sell
163,992
-100
-0.1% -$1.07K 0.03% 583
2024
Q3 		$1.56M Buy
+164,092
New +$1.69M 0.04% 605
2022
Q2 		– Sell
-416
Closed -$869K – 2247
2022
Q1 		$869K Hold
416
– – 0.02% 980
2021
Q4 		$2.04M Sell
416
-2
-0.5% -$12K 0.05% 479
2021
Q3 		$2.63M Sell
418
-11
-3% -$89.2K 0.07% 344
2021
Q2 		$4.04M Hold
429
– – 0.13% 170
2021
Q1 		$3.73M Buy
429
+27
+7% +$255K 0.14% 150
2020
Q4 		$3.06M Hold
402
– – 0.11% 166
2020
Q3 		$2.64M Sell
402
-11
-3% -$82.7K 0.16% 155
2020
Q2 		$3.09M Buy
413
+96
+30% +$697K 0.21% 113
2020
Q1 		$2.27M Buy
317
+148
+88% +$1.57M 0.19% 140
2019
Q4 		$2.62M Buy
169
+22
+15% +$232K 0.23% 111
2019
Q3 		$1.39M Buy
147
+30
+26% +$335K 0.13% 222
2019
Q2 		$1.84M Hold
117
– – 0.17% 159
2019
Q1 		$1.97M Buy
+117
New +$1.75M 0.19% 125
2018
Q3 		– Sell
-9
Closed -$114K – 787
2018
Q2 		$114K Buy
9
+1
+13% +$11.9K 0.01% 676
2018
Q1 		$94K Buy
8
+2
+33% +$22.5K 0.01% 649
2017
Q4 		$54K Buy
+6
New +$25.8K 0.01% 673

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Boothbay Fund Management's AVTX Position: Q1 2026 in Review

Boothbay Fund Management increased its Avalo Therapeutics (AVTX) stake by 60% in Q1 2026, buying an estimated $1.91M and bringing the position to 324,258 shares worth $4.84M. The position accounts for 0.06% of the portfolio, ranked #334.

Boothbay Fund Management first reported a position in AVTX in Q4 2017 and has held it in 22 quarters since. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Boothbay Fund Management held 324,258 shares of Avalo Therapeutics worth $4.84M as of Q1 2026.
  • Boothbay Fund Management bought 122,131 Avalo Therapeutics shares in Q1 2026, an estimated $1.91M.
  • Avalo Therapeutics made up 0.06% of Boothbay Fund Management's portfolio in Q1 2026, its #334 holding.
  • Boothbay Fund Management first reported a position in Avalo Therapeutics in Q4 2017 and has held it in 22 quarters since.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.